BioCentury | Nov 18, 2019

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BioCentury | Jan 24, 2019
Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
BioCentury | Jan 4, 2019
Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
BioCentury | Nov 9, 2018
Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
BioCentury | Nov 8, 2018
Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases. Cabaletta's co-founders include Michael Milone, an...
BioCentury | Jun 20, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Low esophageal levels of SPINK7 could help diagnose eosinophilic esophagitis. In esophageal tissue samples, SPINK7 protein and mRNA levels were lower in patients with eosinophilic esophagitis than in healthy volunteers, and the...
BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Desmoglein 3 (DSG3)

Autoimmune disease INDICATION: Pemphigus vulgaris (PV) Cell culture and mouse studies suggest chimeric autoantigen receptor (CAAR) T cells specific for DSG3 could help treat PV. The DSG3 CAAR T cells consisted of human T cells...
BioCentury | Feb 28, 2013
Tools & Techniques

Cardiomyocytes acting like adults

...cells that help glue the cells together, including junction plakoglobin (JUP) , desmoplakin (DSP) , desmoglein 2 (DSG2)...
BioCentury | Jan 31, 2013
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Pemphigus vulgaris (PV) Desmoglein 1 (DSG1); DSG3 In vitro and mouse studies identified a DSG-binding peptide that could help treat PV. In a mouse...
BioCentury | Nov 3, 2011
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Desmoglein 2 (DSG2) Studies in mice suggest...
Items per page:
1 - 10 of 11